ICUI

ICU Medical, Inc.

ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others.

ICU Medical, Inc. (ICUI) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.4 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 74.6
EV / EBITDA 15.5
Rev Growth YoY 4.4%
Gross Margin 38.9%
Price Return 3M -2.6%
Price Return 12M 28.0%
Catalyst Signal 0.00
Market Cap $4.5B
TTM Revenue $2.2B
Price / Sales 2.0
ROE 2.8%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C (2.4) C- (2.0) B- (3.1) B (3.4) C+ (2.6) C+ (2.7)
2026-11-05 C- (1.9) D+ (1.8) B- (3.1) B+ (3.5) C+ (2.7) C+ (2.6)
2026-10-29 C- (2.0) D+ (1.7) B- (3.1) B (3.4) C+ (2.7) C+ (2.6)
2026-10-22 C- (2.0) D+ (1.7) B- (3.1) B (3.3) C+ (2.6) C+ (2.6)
2026-10-15 C- (2.0) D+ (1.8) B- (3.1) B- (3.1) C+ (2.6) C+ (2.5)
Page 1 of 8
…